PatientsVille.com Logo

COMPLETED SUICIDE and Fluoxetine

PatientsVille

COMPLETED SUICIDE Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for COMPLETED SUICIDE

COMPLETED SUICIDE treatment research studies

Fluoxetine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Fluoxetine Side Effects

Completed Suicide (381)
Depression (279)
Suicidal Ideation (227)
Anxiety (216)
Serotonin Syndrome (211)
Confusional State (197)
Nausea (188)
Toxicity To Various Agents (188)
Headache (187)
Death (185)
Agitation (184)
Condition Aggravated (184)
Cardiac Arrest (175)
Fatigue (175)
Dizziness (168)
Feeling Abnormal (161)
Respiratory Arrest (158)
Poisoning (157)
Tremor (155)
Insomnia (154)
Overdose (102)
Product Substitution Issue (102)
Vomiting (97)
Dyspnoea (96)
Convulsion (96)
Suicide Attempt (94)
Hyperhidrosis (89)
Somnolence (87)
Aggression (85)
Fall (83)
Malaise (81)
Cardio-respiratory Arrest (80)
Intentional Overdose (78)
Pain (75)
Electrocardiogram Qt Prolonged (74)
Loss Of Consciousness (74)
Abnormal Behaviour (74)
Hypotension (73)
Abdominal Pain (70)
Diarrhoea (69)
Dyskinesia (64)
Decreased Appetite (64)
Syncope (63)
Hyponatraemia (62)
Rash (61)
Depressed Mood (59)
Pyrexia (54)
Irritability (53)
Blood Pressure Increased (50)
Asthenia (50)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Can it increase your fertilty

Child has had problems with strattera and fluoxetine mixing what could they be?

I was on 20 mg from age 13-18 and it completely stunted my pubertal growth. I didnt grow an inch AND I hit puberty very late. I have very very short legs, arms, and fingers. This medicine is garbage. It also caused gonadal atrophy, so now I can barle

I'm 18 and was prescribed fluoexitine as a way to gain control of my volatile mood swings and depression. Initially before going on the drug I was skeptical that it was the best thing for me. I was taking two tablets a day and had intense side effect

I'm on my 5th day taking 20 mg of fluoxetine. Is it known to make you cry? I've gone from a practical inability to cry to crying often. Is this a normal side effect?

It really helped me and i love being free of stress.life is to short to live with anxiety every day.FLUOXETINE was the first and the best for me.

My chest has grown since being on Fluoxetine, however i am also on the pill and i know that is partially why, but i'm wondering if Fluoxetine could be also responsible?

Obviously I haven't had an experience with completed suicide, yet. I'm thinking about my troubles and how easy it would be to try to stop the emotional turmoil.

Wats up ppl i love it

Yes I have had mild Fluoxetine side effects. I am only 12 years old but it was prescribed to me by a doctor.

Well to all of you that have finished Rifnah well done.I've now completed the course of six mounths.I am Just woundering how long it takes to get out of your system? Any ideas?

2010 My husband was having back pain and was given Meloxicam. He took a few and didn't like how they made him feel. He committed suicide 2/21/2011. He had 25 pills taken from the original bottle. I don't know when he sta

A doctor prescribed progesterol to me when I was about 29 and it sent me into a severe depression. I was crying 24/7 and was contemplating suicide. I quite taking it and then I was better.

Completed course of interferon and ribavirn for Hepititis C. Fell pregnant 5 months after completion of treatment and gave birth to a baby boy weighing 7.6 lbs. He has Trisomy 21. He was born with Persisitant Pulmonary hypertension and a VSD. I do no

Does this drug make a person feel to commit suicide?

Fervex works very well, better than Tera Flu and Neo Citron. Are you crazy to do the drugs coctail? For sure you commit a suicide.

Have you experienced a suicide attemp while on Sotolol?

Hi Bob, Like you my mum is 59 and has GBM4. She also has completed her 6 weeks radiation and chemo. She was off everything for the last 4 weeks and is starting a higherdosage (150mg) of temodar next month. Good to talk to aomeone who is

Hi, I Don't think I have Osteonecrois even though me jaw started hurting about 6 month's ago. I have been taking Actonel for 16 years now because. because of my Osteoporosis. I didn't have this infliction until I completed three trips to Chernoby

How long after completing her prescription of Roacutan is before my daughter can put a clour in her hair without her hair falling out? She completed the course at the end of January2010.

COMPLETED SUICIDE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting "Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"
Condition: Cerebral Infarction
Interventions: Drug: Fluoxetine;   Drug: Placebo of Fluoxetine
Outcome Measures: Slope of the curve of recruitment of the PEMs;   Slope of recruitment of the PEMs;   Index finger force control in paretic hand under time-course of treatment of Fluoxetine;   in index finger force control in non-paretic hand under time-course of treatment of Fluoxetine
2 Not yet recruiting Fluoxetine Prevention Trial
Condition: Cognitive Dysfunction
Interventions: Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Change from baseline in regional cerebral metabolism;   Durability of the protective effect of Fluoxetine;   Change from baseline in neuropsychological (cognitive, functional) test results;   Correlation between cognitive functioning and cerebral metabolism by correlating neuropsychological testing results with PET imaging;   Correlation between inflammatory cytokines and cerebral metabolism by correlating blood cytokine marker levels with PET imaging
3 Unknown  Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure
Condition: Posttraumatic Stress Disorder, Combat-related
Interventions: Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Clinician Administered PTSD Scale;   PTSD Symptom Checklist
4 Recruiting A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine;   Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Mean Change from Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS);   Mean Change from Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale;   Mean Change from Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS);   Mean Change from Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36);   Mean Change from Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS);   Percentage of Participants who Achieve a Response Based on a ≥50% Reduction from Baseline in MADRS Total Score;   Percentage of Participants who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks;   Mean Change from Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS);   Mean Change from Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)
5 Recruiting Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
Condition: Stroke
Interventions: Drug: Fluoxetine;   Drug: placebo
Outcome Measures: Fugl-Meyer Motor Scale (FMMS);   Western Aphasia Battery;   Behavioral Inattention Test (BIT);   Functional Independence Measure
6 Recruiting Effectiveness Study to Compare Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depression
Condition: Major Depression
Intervention: Drug: venlafaxine,Fluoxetine
Outcome Measures: change of 24-item Hamilton Rating Scale for Depression total score;   the mean change of HAMD-24 subscale score in items 10, 11, 12, 13 (anxiety and somatizations) at endpoint
7 Recruiting Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Fluoxetine + Valsartan;   Drug: Fluoxetine + Placebo
Outcome Measures: Hamilton Depression Rating Scale (HDRS);   fasting plasma glucose;   fasting serum insulin;   C-reactive Protein, and IL-6
8 Recruiting Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage
Conditions: Intracerebral Hemorrhage;   Motor Impairment
Interventions: Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Fugl Meyer Motor Scale score;   Barthel Index;   modified Rankin Scale;   NIH Stroke Scale
9 Unknown  Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Fluoxetine
Outcome Measures: The primary endpoint will be change in pulmonary vascular resistance (PVR) measured by right heart catheterization after three months of therapy.;   Efficacy, Safety and tolerability endpoints will include change between baseline and three month QIDS-SR depression scale, systolic and diastolic blood pressure (systemic) and tabulation of adverse events
10 Unknown  Pharmacogenomics Studies of Antidepressants
Conditions: Major Depressive Disorder;   Antidepressive Agents;   Pharmacogenetics;   Venlafaxine;   Fluoxetine
Interventions: Drug: Venlafaxine;   Drug: Fluoxetine
Outcome Measures: Hamilton Depression Rating Scale (HDRS);   C-reactive Protein and IL-6;   fasting blood glucose, lipid profiles
11 Recruiting Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
Condition: Severe Mood Dysregulation
Interventions: Drug: lisdexamfetamine;   Drug: Placebo;   Drug: Fluoxetine
Outcome Measures: Clinical Global Impression-Improvement-Severe Mood Dysregulation;   Pediatric Anxiety Rating Scale (PARS);   Children's Depression Rating Scale;   ADHD-IV Rating Scale;   ADHD IV Rating Scale;   Columbia Suicide Severity Scales;   Barnes Akathisia Scale;   Children's Affective Lability Scale;   Physical Symptom Checklist;   Revised Modified Overt Aggression Scale;   Screen for Children's Affective Reactivity;   Affective Reactivity Index
12 Not yet recruiting RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke
Condition: Severe Stroke With Affected Arm Motor Function
Interventions: Drug: Fluoxetine;   Drug: Placebo;   Procedure: eCMIT;   Procedure: Usual Care
Outcome Measures: Grade 4/5 Motor Activity Log (MAL) Arm Use Scale;   Grade 4/5 MAL Arm Use scale;   Grade 4/5 Wolf Motor Function Test Performance Rate score
13 Recruiting Developing Adaptive Treatment Strategies for Children and Adolescents With Obsessive-compulsive Disorder.
Condition: Obsessive-Compulsive Disorder
Interventions: Drug: Fluoxetine;   Behavioral: Group cognitive-behavioral therapy
Outcome Measures: Treatment response status at week 28;   Treatment response status at week 14;   Predictors of treatment response at week 28
14 Recruiting Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes
Conditions: Depression;   Mood Disorder;   Anxiety Disorder;   Healthy
Intervention:
Outcome Measure:
15 Recruiting A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release;   Drug: Fluoxetine;   Drug: placebo
Outcome Measures: Change from baseline to Week 8 visit in the Children's depression rating scale, revised (CDRS-R) total score;   Clinical Global Impression Improvement (CGI-I) score at the Week 8 visit;   CGI-S score change from baseline at the Week 8 visit;   CGI-I response (1 or 2)
16 Recruiting Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)
Conditions: Type 1 Diabetes;   Hypoglycemia Associated Autonomic Failure
Interventions: Drug: Fluoxetine;   Drug: Placebo control
Outcome Measure: Change in Catecholamines
17 Recruiting A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture
Conditions: Major Depressive Disorder;   Depression
Interventions: Drug: Fluoxetine;   Procedure: DCEAS (Hwato®/ Dongbang®);   Procedure: n-CEA (Strietberger®)
Outcome Measures: HAMD-17;   SDS;   PET scanning;   Clinical response;   Remission;   Latency;   Adverse events
18 Recruiting Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
Conditions: Obsessive-Compulsive Disorder;   Anxiety Disorders;   Mental Disorders
Interventions: Drug: Fluoxetine;   Drug: Sertraline;   Drug: Paroxetine;   Drug: Citalopram;   Drug: Fluvoxamine;   Behavioral: Exposure and Response Prevention
Outcome Measures: The change of Yale-Brown Obsessive-Compulsive Scale score;   The change of Beck Depression Inventory(BDI-II) score;   The change of Beck Anxiety Inventory(BAI) score;   The change of Stress Perceived Questionnaire (PSS-10) score;   The change of Behavioral Inhibition/Behavioral Activation System Scales score;   The change of Barratt Impulsiveness Scale 11 (BIS-11) score;   The change of Obsessive Beliefs Questionnaire-44(OBQ-44) score;   The NEO-Five Factor Inventory-Revised (NEO-FFI-R);   The Early Trauma Inventory Self Report-Short Form(ETISR-SF)
19 Recruiting Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder
Conditions: Borderline Personality Disorder;   Suicide
Interventions: Drug: Fluoxetine;   Behavioral: DBT;   Drug: Citalopram
Outcome Measure: Suicidal and self-injurious behavior
20 Recruiting Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study
Condition: Multiple System Atrophy
Interventions: Radiation: PET (Positron Emission Tomography) Study;   Other: Brain MRI (magnetic resonance imaging);   Drug: Fluoxétine / Placebo
Outcome Measures: 18F-MPPF binding potential - Biding potential (BP) under placebo in the raphe nucleus;   18F-MPPF binding potential - Biding potential (BP) in other brain areas;   Clinical parameters (motor handicap, orthostatic hypotension, quality of life, sleep, pain, tiredness);   18F-MPPF binding potential - Biding potential (BP) under placebo in other brain areas;   18F-MPPF binding potential - BP under Fluoxetine in all brain areas